Literature DB >> 19736929

Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance.

Luiz Pedro S de Carvalho1, Gang Lin, Xiuju Jiang, Carl Nathan.   

Abstract

We report here that nitazoxanide (NTZ) and its active metabolite kill replicating and nonreplicating M. tuberculosis at low microg/mL levels. NTZ appears to evade resistance, as we were unable to recover resistant colonies, using up to 10(12) colony forming units. Therefore, NTZ is a novel lead compound that kills replicating and nonreplicating M. tuberculosis by a novel mechanism of action, which appears to bypass the development of resistance.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19736929     DOI： 10.1021/jm9010719

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  51 in total

1.  Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Joseph Salamoun; Michelle Warthan; Paul S Hoffman; Timothy L Macdonald
Journal:  ChemMedChem       Date:  2010-12-29       Impact factor: 3.466

2.  Dehydrozingerone Inspired Styryl Hydrazine Thiazole Hybrids as Promising Class of Antimycobacterial Agents.

Authors:  Girish A Hampannavar; Rajshekhar Karpoormath; Mahesh B Palkar; Mahamadhanif S Shaikh; Balakumar Chandrasekaran
Journal:  ACS Med Chem Lett       Date:  2016-05-13       Impact factor: 4.345

Review 3.  Host-directed therapeutics for tuberculosis: can we harness the host?

Authors:  Thomas R Hawn; Alastair I Matheson; Stephen N Maley; Omar Vandal
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

Review 4.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Paul S Hoffman; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2010-05-18       Impact factor: 2.823

6.  Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain.

Authors:  P Ripani; J Delp; K Bode; M E Delgado; L Dietrich; V M Betzler; N Yan; G von Scheven; T U Mayer; M Leist; T Brunner
Journal:  Oncogene       Date:  2019-12-16       Impact factor: 9.867

Review 7.  Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

Authors:  Adetomiwa A Adeniji; Kirsten E Knoll; Du Toit Loots
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-05       Impact factor: 4.813

8.  Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Authors:  Joseph S Cavanaugh; Ruwen Jou; Mei-Hua Wu; Tracy Dalton; Ekaterina Kurbatova; Julia Ershova; J Peter Cegielski
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

9.  Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture.

Authors:  Elizabeth P Harausz; Keith A Chervenak; Caryn E Good; Michael R Jacobs; Robert S Wallis; Manuel Sanchez-Felix; W Henry Boom
Journal:  Tuberculosis (Edinb)       Date:  2016-03-22       Impact factor: 3.131

10.  Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.

Authors:  Giovanni Piccaro; Federico Giannoni; Perla Filippini; Alessandro Mustazzolu; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.